Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EBMT 2019 | ODYSSEE study: fecal microbiota transplantation in AML

Florent Malard • 4 Apr 2019
EBMT 2019
Acute Myeloid Leukemia Leukemia

Here, Florent Malard, MD, PhD, from Hôpital Saint-Antoine, Paris, France, discusses the multicentre ODYSSEE study at the European Society for Blood and Marrow Transplantation (EBMT) 2019 Annual Meeting, which has been held in Frankfurt, Germany.

More from Florent Malard

Results of a survey investigating fertility and outcomes after CAR T-cell therapy 1:13
Results of a survey investigating fertility and outcomes after CAR T-cell therapy
Florent Malard • 7 Dec 2025
Results of ARES: allogeneic microbiotherapy for ruxolitinib-refractory GvHD with GI involvement 2:08
Results of ARES: allogeneic microbiotherapy for ruxolitinib-refractory GvHD with GI involvement
Florent Malard • 7 Dec 2025
The potential impact of antibiotic exposure before CAR-T on therapeutic outcomes 1:17
The potential impact of antibiotic exposure before CAR-T on therapeutic outcomes
Florent Malard • 31 Mar 2025
The potential of microbiome modulation for preventing and treating acute GvHD 1:04
The potential of microbiome modulation for preventing and treating acute GvHD
Florent Malard • 31 Mar 2025

Related Videos

Targeting mitochondrial metabolism with EB2023 to overcome venetoclax resistance in acute leukemia 1:48
Targeting mitochondrial metabolism with EB2023 to overcome venetoclax resistance in acute leukemia
Michael Savona • 6 Dec 2025
Phase II SAVE study of revumenib-based all-oral therapy in newly diagnosed AML 1:31
Phase II SAVE study of revumenib-based all-oral therapy in newly diagnosed AML
Wei-Ying Jen • 6 Dec 2025
The development and international validation of an unsupervised classification model in AML 1:28
The development and international validation of an unsupervised classification model in AML
Amin Turki • 7 Dec 2025
The potential association of plasma venetoclax level with treatment efficacy in first-line AML 2:08
The potential association of plasma venetoclax level with treatment efficacy in first-line AML
Thomas Cluzeau • 8 Dec 2025
The content of VJHemOnc is intended for healthcare professionals